-
Press Release
Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)
-
Press Release
Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
-
Press Release
Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials
-
Press Release
Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies
-
Press Release
Novartis verzeichnete im zweiten Quartal Umsatzsteigerungen und baute die Pipeline weiter aus; Prognose für das Geschäftsjahr bekräftigt
-
Press Release
Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed
-
Story
Novartis marks 30 years of breakthroughs, building on 250 years of discovery to reimagine what medicine can do next -
Press Release
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
-
Press Release
Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients
-
Press Release
Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
-
Press Release
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
-
Press Release
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026